Bliss GVS Pharma Limited — Board Meeting, 12-05-2025: Outcome of Board Meeting

Bliss GVS Pharma has announced a board meeting approving audited consolidated financial results for the quarter and year ended March 31, 2025, with a clean audit opinion. The board proposed a final dividend of 0.50 paisa per share, subject to shareholder approval. BDO India LLP was re-appointed as Internal Auditor, and AVS & Associates onboarded as Secretarial Auditor for the next five years. The company sold a 51% stake in its step-down subsidiary Greenlife Bliss Healthcare Ltd to an existing Nigerian partner for USD 1.3 million. Up to 12.1 lakh sweat equity shares will be allotted to the MD and VP as non-cash compensation.